Rivaroxaban for Slow Coronary Flow After PCI in STEMI (NCT07195812) | Clinical Trial Compass
Not Yet RecruitingPhase 4
Rivaroxaban for Slow Coronary Flow After PCI in STEMI
60 participantsStarted 2025-10
Plain-language summary
The goal of this clinical trial is to learn if drug Rivaroxaban works to improve slow flow in STEMI patients after PCI in adults. It will also learn about the safety of drug Rivaroxaban. The main questions it aims to answer are:
Does drug Rivaroxaban Reduce the Corrected TIMI Frame Count (cTFC) in 1 Week After PCI ?
Researchers will compare Combination therapy with rivaroxaban (2.5 mg administered twice daily), aspirin (100 mg administered daily), and clopidogrel (75 mg administered daily) to Dual Antiplatelet Therapy to see if drug Combination therapy with rivaroxaban, aspirin works to treat Slow Flow in STEMI Patients After PCI.
Participants will:
Take drug Combination therapy with rivaroxaban (2.5 mg administered twice daily), aspirin (100 mg administered daily), and clopidogrel (75 mg administered daily) or Dual Antiplatelet Therapy every day for 1 months.
Visit the clinic in 7 days、30 days and 365 days for checkups and tests.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age ≥ 18 years, regardless of gender;
* Patients with ST-segment elevation myocardial infarction (STEMI) (meeting the diagnostic criteria of the 2019 Chinese "Guidelines for the Diagnosis and Treatment of Acute ST-Segment Elevation Myocardial Infarction");
* Patients undergoing percutaneous coronary intervention (PCI);
* Patients with slow flow after PCI (TIMI flow grade \> 0 but \< 3);
* Signed informed consent form and willingness to comply with follow-up.
Exclusion Criteria:
* Presence of malignant tumors or diseases with a life expectancy of less than 1 year;
* Coagulation disorders, diagnosed or suspected hematological diseases (excluding mild or moderate anemia);
* Thrombocytopenia (platelet count \< 100 × 10⁹/L); history of severe gastrointestinal diseases or peptic ulcers; active bleeding within the past 3 months or major surgery history; history of intracranial hemorrhage or intracranial aneurysm;
* History of cerebral hemorrhage or ischemic stroke within the past 6 months;
* Patients with cardiogenic shock; systemic infections or immune system diseases; confirmed, highly suspected, or unable to rule out aortic dissection; severe uncontrolled hypertension (systolic blood pressure \> 180 mmHg and/or diastolic blood pressure \> 110 mmHg);
* Current use of rivaroxaban or requiring long-term anticoagulation therapy (e.g., atrial fibrillation);
* Patients with renal insufficiency (eGFR \< 15 mL/min/1.73m²) or hepatic insufficiency (Child-Pugh Clas…
What they're measuring
1
Change in Corrected TIMI Frame Count (cTFC) from baseline within 1 week after PCI
Timeframe: Change from baseline within 1 week
Trial details
NCT IDNCT07195812
SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University